1Ј-Acetoxychavicol acetate (ACA: 1, Fig. 1 ) was first isolated from the rhizomes and seeds of Zingiberaceae plants, including Languas garanga and Alpinia garanga, which have been used as a ginger substitute and a stomach medicine in Southeast Asia.
1Ј-Acetoxychavicol acetate (ACA: 1, Fig. 1 ) was first isolated from the rhizomes and seeds of Zingiberaceae plants, including Languas garanga and Alpinia garanga, which have been used as a ginger substitute and a stomach medicine in Southeast Asia. 1) Recent studies have revealed that ACA (1) exhibits antitumor activities against a wide variety of cancers [2] [3] [4] [5] [6] and anti-tumor-promoting activities towards estrogen-related endometrial carcinogenesis, 4) azoxymethaneinduced colonic aberrant crypt foci, 5) phorbol ester-induced skin tumor promotion. 6) Moreover, ACA (1) has been reported to elicit a variety of biological activities, including antioxidant, anti-inflammatory, and anti-human immunodeficiency virus (HIV) activity, [7] [8] [9] induction of nitric oxide (NO) synthase gene expression, 8) and inhibition of interferon-b production. 10) We (Kizaki's group) have recently reported that ACA (1) induces the apoptosis of myeloid leukemia cells in vitro and in vivo through inhibition of NFkB-related functions, 11, 12) suggesting ACA (1) is a candidate therapeutic agent for the treatment of myeloid leukemia. ACA (1) induces cell apoptosis through two different pathways in myeloid leukemia cells, i.e., through generation of reactive oxygen species (ROS) and through activation of the Fas-pathway. 11 ) ACA (1) also inhibited the cellular growth of myeloma cells in association with the down-regulation of NF-kB activity, affecting both the caspase 8 and 9 pathways. 13) Azuma et al. recently reported structure-activity relationship studies of ACA (1) for apoptotic activity towards human leukemia HL-60 cells, 14) showing that (i) the two acetyl groups and the unsaturated double bond between the Cb and Cg positions of ACA (1) are essential for the activity, and (ii) the configuration at the a-position of ACA (1) does not affect the activity. Based on these results, we synthesized several ACA (1) analogs and examined their cell-growth-inhibitory activity using human leukemia HL-60 cells. Compound 2 ( Fig. 1) , a benzhydrol diacetate derivative, possessed moderate HL-60 cell-growth-inhibitory activity with an IC 50 value of 3.5 mM, i.e., it is slightly less potent than ACA (1, IC 50 ϭ2.0 mM). This led us to plan detailed structure-activity relationship studies of benzhydrol analogs developed from 2 as a lead compound.
Here we describe structural development of benzhydroltype potent HL-60 cell-growth inhibitors, guided by quantitative structure-activity relationship (QSAR) analysis.
Chemistry The synthesis of compound 2 and its analogs is outlined in Charts 1-3. Briefly, the hydroxyl group of 4-hydroxybenzaldehyde (9) was protected with tert-butyldimethylchlorosilane (TBS-Cl), followed by treatment with appropriate Grignard or aryllithium reagents (generated from aryl bromide by treatment with n-butyllithium) to afford the intermediates 11a-d. Deprotection of the TBS group was performed with tetra-n-butylammonium fluoride (TBAF), and then acetylation with acetic anhydride afforded 3a-d. On the other hand, protection of the hydroxyl group of 4-bromophenol (14) with TBS-Cl, followed by treatment with n-butyllithium, gave aryllithium species, which were quenched with various benzaldehydes to give intermediates 11e-h and 13a. Deprotection of the TBS group with TBAF, and successive acetylation with acetic anhydride afforded 3e-h and 5a. Sulfoxide 3j and sulfone 3k were prepared from 3c. Oxidation of 3c with 1 or 2 eq of m-chloroperbenzoic acid gave 3j and 3k, respectively. Compounds 3i and 4a-g were synthesized by our method using t Bu 4 ZnLi 2 . 15, 16) As shown in Chart 2, iodobenzenes 16a-h were treated with t Bu 4 ZnLi 2 (prepared from ZnCl 2 and t BuLi), and the resulting organozincate intermediates were quenched with 4-tert-butyldimethylsilyloxybenzaldehyde (10) to afford intermediates 11i and 12a-g. Finally, deprotection of the TBS group with TBAF and subsequent acetylation with acetic anhydride gave 3i and 4a-g, respectively. 50 values of the 20 compounds were rather similar (2.1-7.7 mM) and no apparent electronic substituent effects were observed. Reproducibility of the assay results was good. Therefore, we judged that the IC 50 values described in Table 1 are reliable, which led us to explore the QSAR of the 20 compounds. The QSAR analysis was performed by using the QSAR applications of the molecular operating environment (MOE 2006) 17) with the genetic algorithm analysis applying all descriptors of MOE (184 kinds). The correlation plot between pIC 50 values obtained from observed IC 50 values and calculated pIC 50 values according to Eq. 1 is displayed in Fig. 2 .
The meanings of the parameters of Eq. 1 are as follows: (i) BCUT 18) _SMR 19) _2: descriptor of molar refraction and coupling matrix, (ii) PEOE 20) _VSA 21) _PNEG: surface area of negative charge moiety, (iii) b_1rotR: rate of rotatable single bond, and (iv) PetitjeanSC 22) : (diameter-radius)/radius. The BCUT_SMR_2, b_1rotR, and petitjeanSC parameters indicate that cell-growth-inhibitory activity tends to rise in proportion to the bulkiness of the functional group on the phenyl (B) ring. In addition, the negative coefficient of the PEOE_VSA_PNEG parameter suggests that compounds pos- 
sessing a substituent with a negative charge on a phenyl (B) ring would show reduced cell-growth-inhibitory activity.
Based on this information, we designed compounds with 4-trimethylsilylphenyl (3l), 4-phenylphenyl (3m), 3,5-diphenylphenyl (4h), 1-naphthyl (6), 2-naphthyl (7), and 9-anthracenyl (8) moieties. All of them, except for 3l, were prepared using the same procedure as shown in Chart 1 (Chart 4). For 3l, we adopted Grignard reaction instead, because of the low yield with our standard method.
As expected, all the newly synthesized compounds showed the same or higher cell-growth-inhibitory activity than 2 ( Table 2 ). The compounds bearing a phenyl group(s) on the phenyl (B) ring, such as 3m and 4h, showed more potent activity than 2 (3m: IC 50 ϭ1.7 mM; 4h: IC 50 ϭ1.1 mM). Compounds 6-8 also exhibited higher inhibitory activity than 2. The 1-naphthyl derivative (6) showed far more potent activity than the regioisomeric 2-naphthyl derivative (7). Especially, 6 and 8 were found to have activity an order of magnitude higher than that of 2, with IC 50 values of 0.29 and 0.12 mM, respectively. The compounds with a trimethylsilyl group at the 4Ј-position on the phenyl (B) ring, 3l, and with a 2-naphthyl group, 7, possessed the same or slightly higher activity than 2. These results suggest that (i) compounds bearing a substituent which maintains the p-conjugated system on the phenyl (B) ring tend to show higher cell-growth-inhibitory activity; (ii) the introduction of a substituent on the phenyl (B) ring at a meta-position(s) is better than that at the paraposition; (iii) the p-conjugated system between the phenyl (B) ring and its substituent should preferably consist of a ring-fused structure.
According to Azuma's report, 14) the enantiomers of ACA (1) showed the same cell-growth-inhibitory activity towards HL-60 cells. We also compared the cell-growth-inhibitory activities of the enantiomers of our compound 3m. Separation of the enantiomers of 3m was performed by chiral HPLC using DAICEL CHIRALPAK AD-H. As shown in Table 3 , the enantiomers of 3m exhibited similar cellgrowth-inhibitory activities. We confirmed that racemization of the enantiomers of 3m did not occur under the experimental conditions (data not shown). This result suggests that the activities of the enantiomers of 3m are essentially the same.
In conclusion, we have developed analogs of ACA (1) with potent cell-growth-inhibitory activity, based on QSAR analysis. Compound 8 was 16 to 17 times more potent than ACA (1, IC 50 ϭ2.0 mM), having the IC 50 value of 0.12 mM. Further structural development and biological studies are in progress. 
4-(tert-Butyldimethylsilyloxy)-a a-(4-methylphenyl)benzyl Alcohol (11b) [Typical Procedure B]
To a solution of p-bromotoluene (500 ml, 4.20 mmol) in dry THF (5.0 ml) was added n-butyllithium (1.65 M in THF, 1.25 ml, 2.06 mmol) at Ϫ78°C. Then, 10 (505 mg, 2.1 mmol) was added dropwise. The mixture was stirred for 3 h at Ϫ78°C, saturated aqueous NH 4 Cl solution was added and the whole was extracted with ethyl acetate. The organic layer was dried with MgSO 4 , and concentrated. The residue was purified by column chromatography (ethyl acetate/hexaneϭ1/6) to give 11b (335 mg, 41%) as a pale yellow oil: (2.20 mmol) in THF at Ϫ78°C, and the solution was warmed to 0°C, and stirred for 2 h. Then, 0.74 ml of 10 (3 mmol) added. The mixture was allowed to warm to room temperature, stirred for 15 h, quenched by adding saturated aqueous NH 4 Cl solution and 2 N HCl, and extracted with Et 2 O. The organic layer was washed with brine, dried over Na 2 SO 4 , and concentrated. The residue was purified by column chromatography (ethyl acetate/hexaneϭ1 : 5) to give 12a as a colorless oil (366 mg, 49%): 4-(tert-Butyldimethylsilyloxy)-a a-(4-trimethylsilylphenyl)benzyl Alcohol (11l) To a solution of magnesium (200 mg, 7.5 mmol) activated with iodine (5.0 mg) in Et 2 O was added dropwise 10 (342 mg, 1.50 mmol) at room temperature. This solution was added dropwise to a solution of 1 (236 mg, 1.0 mmol) in dry THF (3.0 ml) at Ϫ78°C. The mixture was stirred for 1.5 h at Ϫ78°C, brine was added and the whole was extracted with ethyl acetate. The organic layer was dried over MgSO 4 , and concentrated. The residue was purified by column chromatography (ethyl acetate : hexaneϭ 1 : 10) to give 11l (198 mg, 52%) as a pale yellow oil: To a solution of 11a (192 mg, 0.58 mmol) in dry THF (5.0 ml) was added TBAF (1.0 M in THF, 0.5 ml, 0.500 mmol) at 0°C. The reaction mixture was stirred for 1 h at the same temperature, then concentrated under reduced pressure. The residue was taken up in pyridine (4.0 ml) and acetic anhydride (500 ml, 1.47 mmol) was added to the solution at room temperature. The mixture was stirred for 3 h at room temperature, NH 4 Cl aq. was added and the whole was extracted with ethyl acetate. The organic layer was dried with MgSO 4 , and concentrated. The residue was purified by column chromatography (ethyl acetate/hexaneϭ1/4) to give 3a (27.0 mg, 51%) as a colorless oil: 
